Expert Panel to Discuss Importance of an Integrated Approach to Strategic Drug Development at Bio-Europe

Share Article

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Dr. Christelle Dagoneau, Director, Business Development for biologics at Catalent, is to participate in an expert panel at the forthcoming BIO-Europe conference, which will be held at KoelnMesse, Congress Center North, Cologne, Germany from Nov. 7 to 9, 2016.

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Dr. Christelle Dagoneau, Director, Business Development for biologics at Catalent, is to participate in an expert panel at the forthcoming BIO-Europe conference, which will be held at KoelnMesse, Congress Center North, Cologne, Germany from Nov. 7 to 9, 2016.

The panel, “Covering all the bases: An integrated approach to strategic drug development,” will take place on Monday, Nov. 7 at 9 a.m., and will examine the elements that are essential for a drug to get to market including a commercialization strategy, a financial road map, a regulatory plan and a business development strategy. The workshop, which will also feature industry experts from Charles River, Vetter, Bayer and Covance, will work through how these four dimensions of drug development not only contribute to success, but also how they need to work together to achieve scientific and commercial success.

Dr. Dagoneau, has been involved in the design of biologics and biosimilar development programs at Catalent for the past five years. Prior to joining Catalent, she served as Head of Marketing and Sales at PX'Therapeutics for six years, and held additional commercial, marketing and research funding roles, both in France and in the United Kingdom, between 2001 and 2005. Dr. Dagoneau holds a doctorate in Organic Chemistry and a master’s in Technology & Business Management, both obtained from Grenoble Business School.

For further information on BIO-Europe visit: https://ebdgroup.knect365.com/bioeurope/ or to arrange a meeting with Dr. Dagoneau at the conference, contact Richard Kerns at NEPR richard(at)nepr(dot)eu.

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 9,500 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2016 generated $1.85 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey.

For more information about Catalent Biologics, visit http://www.catalentbiologics.com
For more information about Catalent Pharma Solutions, visit http://www.catalentbiologics.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Halling

Richard Kerns
Northern Exposure PR
+44 7974 579202
Email >
Visit website